Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LM-108 + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LM-108 | LM 108|LM108 | CCR8 Antibody 9 | LM-108 is a monoclonal antibody that targets CCR8 expressed on regulatory T cells and inhibits downstream signaling, potentially leading to increased antitumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2504), NCI Drug Dictionary). | |
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05199753 | Phase Ib/II | LM-108 LM-108 + unspecified PD-1 antibody | Study of LM-108 as a Single Agent or in Combination With Anti-PD-1 Antibody in Subjects With Advanced Solid Tumours | Recruiting | AUS | 0 |
NCT05255484 | Phase Ib/II | LM-108 + unspecified PD-1 antibody LM-108 | Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours | Terminated | USA | 0 |